Oral Insulin Delivery in Diabetic Rats by PLGA Nanoparticles Combined with a Protease Inhibitor (N-Ethylmaleimide)
Nanoparticles have shown a certain potential to overcome the drawbacks of oral peptide delivery in the gastrointestinal tract such as low peptide stability and permeability. Insulin PLGA NP were prepared using a modified double emulsion solvent evaporation technique. Insulin PLGA NP were composed fr...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
University of Huddersfield Press,
2019-04-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_1d04c8dc6e3c4532882c14a36e86c9e5 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Ahmed M Faheem |e author |
| 700 | 1 | 0 | |a Dalia Abdeĺkader |e author |
| 700 | 1 | 0 | |a Mohamed A. Osman |e author |
| 700 | 1 | 0 | |a Paul A. McCarron |e author |
| 700 | 1 | 0 | |a Sanaa A. El-Gizawy |e author |
| 245 | 0 | 0 | |a Oral Insulin Delivery in Diabetic Rats by PLGA Nanoparticles Combined with a Protease Inhibitor (N-Ethylmaleimide) |
| 260 | |b University of Huddersfield Press, |c 2019-04-01T00:00:00Z. | ||
| 500 | |a 10.5920/bjpharm.588 | ||
| 500 | |a 2058-8356 | ||
| 520 | |a Nanoparticles have shown a certain potential to overcome the drawbacks of oral peptide delivery in the gastrointestinal tract such as low peptide stability and permeability. Insulin PLGA NP were prepared using a modified double emulsion solvent evaporation technique. Insulin PLGA NP were composed from human insulin (5 mg) encapsulated in PLGA 2.5% (w/v) mixed with PEG (2kDa, 5% w/w) and the external aqueous phase contained 1.25% of PVA. The resulting nanoparticles of 202.6 nm diameter and loaded with 33.86 μg insulin per mg of polymer were utilised in this study to examine the hypoglycaemic effect after combination with a protease inhibitor, N-Ethylmaleimide. | ||
| 546 | |a EN | ||
| 690 | |a diabetes mellitus | ||
| 690 | |a nanoparticles | ||
| 690 | |a human insulin | ||
| 690 | |a protease inhibitor | ||
| 690 | |a Pharmacy and materia medica | ||
| 690 | |a RS1-441 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n British Journal of Pharmacy, Vol 4, Iss 1 (2019) | |
| 787 | 0 | |n https://www.bjpharm.org.uk/article/id/588/ | |
| 787 | 0 | |n https://doaj.org/toc/2058-8356 | |
| 856 | 4 | 1 | |u https://doaj.org/article/1d04c8dc6e3c4532882c14a36e86c9e5 |z Connect to this object online. |